IL-28B基因多态性对慢性HBV患者抗病毒治疗疗效的预测价值

Prediction value of IL-28B gene polymorphism on antiviral curative effect in patients with chronic hepatitis B

目的探索IL-28B基因在慢性HBV患者抗病毒疗效中的作用。方法对HBV病毒e抗原(HBeAg)阳性的205例慢性乙型肝炎患者采用干扰素(PEG-IFN)的抗病毒治疗方法,采用TapManSNP基因分析法检测IL-28Brs12980275和rs12979860的基因型,并分析基因型与HBeAg血清转化的关系。结果 205例患者中有6例基因型不确定,剩余的199例患者IL-28B的rs12980275和rs12979860基因型比率分别为AA 77%、AG 19%、GG 5%和CC 76%、CT 20%、TT 4%。IL-28B基因型与HBeAg血清转化显著相关(P<0.01)。在rs12980275基因型上,通过HBV基因型、年龄、HBV水平及丙氨酸转氨酶和联合治疗,血清转化调整AA和AG/GG的优势比为3.16。对于rs12979860也得到了相似的结果。IL-28B也与乙型肝炎表面抗原清除有关。结论 IL-28B与HBeAg阳性慢性乙型肝炎患者抗病毒治疗疗效有关系。

Objective To investigate the role of IL-28B gene on the antiviral curative effect in the patients with chronic hepatitis B.Methods 205 HBeAg-positive patients treated with the antiviral therapy of pegylation interferon（PEG-IFN）were detected the IL-28B rs12980275 and rs12979860 genotypes by TapManSNP genotyping assay and the relationship between the IL-28B genotypes and HbeAg seroconversion at end of treatment was analyzed.Results Among 205 cases,6 cases of genotype were uncertainty,the frequencies of IL-28B genotypes in other 199 cases were 77%,19%,5% for AA,AG,GG genotypes at rs12980275 and 76%,20%, 4%,for CC/CT/TT genotypes at rs12979860 respectively.The IL-28B polymorphisms were significantly correlated with the HbeAg seroconversion at the end of PEG-IFN treatment （P =0.001）.In rs12979860 genotype,by the HBV genotyp,age,HBV lev-el,ALT and the combined therapy,the odds ratio （OR）of AA versus AG/GG was adjusted to 3.16 by HbeAg seroconversion.The similar result also obtained for the rs12980275 genotype.The IL-28B genotype was also associated with the HBsAg clearance.Con-clusion The IL-28B gene polymorphism is associated with the antiviral curative effect in the patients with HBeAg positive chronic hepatitis B.